Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

Loading news article.

Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints | WAPE

Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints

Article summary

Related companies

Comments —